Meeting
2023 ASCO Annual Meeting
Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Arun Azad
Peter MacCallum Cancer Centre, Melbourne, Australia
Arun Azad , Karim Fizazi , Nobuaki Matsubara , Peter C.C. Fong , Joan Carles , Neal D. Shore , Ugo De Giorgi , Robert J. Jones , Lawrence Ivan Karsh , Jae Young Joung , Andre P. Fay , Glenn Liu , Steven M. Yip , Stefanie Zschaebitz , Julia F. Hopkins , Nicola Di Santo , Xun Lin , Marielena Mata , Douglas Laird , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03395197
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5056)
DOI
10.1200/JCO.2023.41.16_suppl.5056
Abstract #
5056
Poster Bd #
150
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.
First Author: Karim Fizazi
Poster
2021 ASCO Annual Meeting
TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2019 ASCO Annual Meeting
TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
First Author: Elena Castro